Blood Marker Study for Liver Disease Patients Starting Ursodeoxycholic Acid Treatment
Checks whether blood markers predict how adults with primary biliary cholangitis respond to ursodeoxycholic acid.
Plain-language title generated from the registry record
Registry title: sCD163 in PBC Patients - Assessment of Treatment Response
Key facts
- Where
- Aarhus C, DenmarkSee the site
Where in Denmark
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, DenmarkAarhus C, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT02931513
- Record updated
- 12 August 2022
- Original description
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment.Read full original descriptionShow less
Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCA
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment.
sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.
Inclusion: Newly diagnosed with Primary biliary cholangitis; No treatment with UDCA.
Exclusion: Expected liver transplantation within 6 months; Liver cancer; Patient under 18 years; Expected lifetime under 6 months; Cirrhosis from other causes.